Homology Medicines (FIXX) Short Interest Ratio & Short Volume

Short interest is the volume of Homology Medicines shares that have been sold short but have not yet been covered or closed out. As of February 29th, traders have sold 338,700 shares of FIXX short. 0.81% of Homology Medicines' shares are currently sold short. Learn More on Homology Medicines' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. FIXX shares currently have a short interest ratio of 1.0. Learn More on Homology Medicines's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.81% of Homology Medicines' floating shares are currently sold short.

Homology Medicines saw a increase in short interest in February. As of February 29th, there was short interest totaling 338,700 shares, an increase of 5.1% from the previous total of 322,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Homology Medicines currently has issued a total of 58,130,000 shares. Some of Homology Medicines' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Homology Medicines currently has a public float of 41,980,000 shares.

0.81% of Homology Medicines' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Homology Medicines: Avidity Biosciences, Inc. (13.47%), Ultragenyx Pharmaceutical Inc. (6.28%), Akero Therapeutics, Inc. (9.82%), Perrigo Company plc (3.59%), Zai Lab Limited (8.24%), Viking Therapeutics, Inc. (23.97%), PTC Therapeutics, Inc. (7.52%), Crinetics Pharmaceuticals, Inc. (11.05%), Merus (9.60%), Catalyst Pharmaceuticals, Inc. (7.34%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.39 billion), General Motors ($3.88 billion), Super Micro Computer, Inc. ($3.51 billion), Charter Communications, Inc. ($3.22 billion), Occidental Petroleum Co. ($3.13 billion), Tractor Supply ($2.76 billion), Coinbase Global, Inc. ($2.63 billion), Suncor Energy Inc. ($2.48 billion), Moderna, Inc. ($2.04 billion), and Royal Caribbean Cruises Ltd. ($1.87 billion). View all of the most shorted stocks.

Short selling FIXX is an investing strategy that aims to generate trading profit from Homology Medicines as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Homology Medicines occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of FIXX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including FIXX, twice per month. The most recent reporting period available is February, 29 2024.